Nikunj Patel

Nikunj Patel

Auto-generated profile, based on publicly available information

Nikunj Patel

Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL 34243, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2005 in Journal of Neuroinflammation
Verified
Journal Article
Open access
NPNikunj S Patel
Nikunj S Patel
DPDaniel Paris
Daniel Paris
VMVenkatarajan Mathura
Venkatarajan Mathura
AQAmita N Quadros
Amita N Quadros
FCFiona C Crawford
Fiona C Crawford
MMMichael J Mullan
Michael J Mullan
Background: Inflammation is believed to play an important role in the pathology of Alzheimer's disease (AD) and cytokine production is a key pathologic event in the progression of inflammatory cascades. The current study characterizes the cytokine expression profile in the brain of two transgenic mouse models of AD (TgAPPsw and PS1/APPsw) and explores the correlations between cytokine production and the level of soluble and insoluble forms of Aβ.Methods: Organotypic brain slice cultures from 15-month-old mice (TgAPPsw, PS1/APPsw and control littermates) were established and multiple cytokine levels were analyzed using the Bio-plex multiple cytokine assay system. Soluble and insoluble forms of Aβ were quantified and Aβ-cytokine relationships were analyzed.Results: Compared to control littermates, transgenic mice showed a significant increase in the following pro-inflammatory cytokines: TNF-α, IL-6, IL-12p40, IL-1β, IL-1α and GM-CSF. TNF-α, IL-6, IL-1α and GM-CSF showed a sequential increase from control to TgAPPsw to PS1/APPsw suggesting that the amplitude of this cytokine response is dependent on brain Aβ levels, since PS1/APPsw mouse brains accumulate more Aβ than TgAPPsw mouse brains. Quantification of Aβ levels in the same slices showed a wide range of Aβ soluble:insoluble ratio values across TgAPPsw and PS1/APPsw brain slices. Aβ-cytokine correlations revealed significant relationships between Aβ1–40, 1–42 (both soluble and insoluble) and all the above cytokines that changed in the brain slices.Conclusion: Our data confirm that the brains of transgenic APPsw and PS1/APPsw mice are under an active inflammatory stress, and that the levels of particular cytokines may be directly related to the amount of soluble and insoluble Aβ present in the brain suggesting that pathological accumulation of Aβ is a key driver of the neuroinflammatory response.

1 January 2010 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
DPDaniel Paris
Daniel Paris
NGNowell J Ganey
Nowell J Ganey
VLVincent Laporte
Vincent Laporte
NPNikunj S Patel
Nikunj S Patel
DBDavid Beaulieu-Abdelahad
David Beaulieu-Abdelahad
MMMichael J Mullan
Michael J Mullan
Aβ deposits represent a neuropathological hallmark of Alzheimer's disease (AD). Both soluble and insoluble Aβ species are considered to be responsible for initiating the pathological cascade that eventually leads to AD. Therefore, the identification of therapeutic approaches that can lower Aβ production or accumulation remains a priority. NFκB has been shown to regulate BACE-1 expression level, the rate limiting enzyme responsible for the production of Aβ. We therefore explored whether the known NFκB inhibitor celastrol could represent a suitable compound for decreasing Aβ production and accumulation in vivo.

1 January 2011 in International Journal of Alzheimer's Disease
Verified
Journal Article
Open access
PDF file
FMFarzaneh Modarresi
Farzaneh Modarresi
MFMohammad Faghihi
Mohammad Faghihi
NPNikunj S. Patel
Nikunj S. Patel
BSBarbara G. Sahagan
Barbara G. Sahagan
CWClaes Wahlestedt
Claes Wahlestedt
MLMiguel Lopez-Toledano
Miguel Lopez-Toledano
Background. Alzheimer′s disease (AD) is a devastating neurological disorder and the main cause of dementia in the elderly population worldwide. Adult neurogenesis appears to be upregulated very early in AD pathogenesis in response to some specific aggregates of beta‐amyloid (Aβ) peptides, exhausting the neuronal stem cell pools in the brain. Previously, we characterized a conserved nonprotein‐coding antisense transcript for β‐secretase‐1 (BACE1), a critical enzyme in AD pathophysiology. We showed that the BACE1‐antisense transcript (BACE1‐AS) is markedly upregulated in brain samples from AD patients and promotes the stability of the (sense) BACE1 transcript. In the current paper, we examine the relationship between BACE1, BACE1‐AS, adult neurogenesis markers, and amyloid plaque formation in amyloid precursor protein (APP) transgenic mice (Tg‐19959) of various ages. Results. Consistent with previous publications in other APP overexpressing mouse models, we found adult neurogenesis markers to be noticeably upregulated in Tg‐19959 mice very early in the development of the disease. Knockdown of either one of BACE1 or BACE1‐AS transcripts by continuous infusion of locked nucleic acid‐ (LNA‐) modified siRNAs into the third ventricle over the period of two weeks caused concordant downregulation of both transcripts in Tg‐19959 mice. Downregulation of BACE1 mRNA was followed by reduction of BACE1 protein and insoluble Aβ. Modulation of BACE1 and BACE1‐AS transcripts also altered oligomeric Aβ aggregation pattern, which was in turn associated with an increase in neurogenesis markers at the RNA and protein level. Conclusion. We found alterations in the RNA and protein concentrations of several adult neurogenesis markers, as well as non‐protein‐coding BACE1‐AS transcripts, in parallel with the course of β‐amyloid synthesis and aggregation in the brain of Tg15999 mice. In addition, by knocking down BACE1 or BACE1‐AS (thereby reducing Aβ production and plaque deposition), we were able to modulate expression of these neurogenesis markers. Our findings suggest a distortion of adult neurogenesis that is associated with Aβ production very early in amyloid pathogenesis. We believe that these alterations, at the molecular level, could prove useful as novel therapeutic targets and/or as early biomarkers of AD.

1 March 2004 in Angiogenesis
Verified
Journal Article
Closed access
PDF file
DPDaniel Paris
Daniel Paris
KTKirk Townsend
Kirk Townsend
AQAmita Quadros
Amita Quadros
JHJames Humphrey
James Humphrey
JSJiazhi Sun
Jiazhi Sun
MMMichael Mullan
Michael Mullan

1 August 2004 in Neuroscience Letters
Verified
Journal Article
Closed access
DPDaniel Paris
Daniel Paris
NPNikunj Patel
Nikunj Patel
ADAnthony DelleDonne
Anthony DelleDonne
AQAmita Quadros
Amita Quadros
RSRobert Smeed
Robert Smeed
MMMichael Mullan
Michael Mullan

1 September 2003 in Neurological Research
Verified
Journal Article
Closed access
DPDaniel Paris
Daniel Paris
JHJames Humphrey
James Humphrey
AQAmita Quadros
Amita Quadros
NPNikunj Patel
Nikunj Patel
RCRobert Crescentini
Robert Crescentini
MMMichael Mullan
Michael Mullan
A beta peptides are the major protein constituents of Alzheimer's disease (AD) senile plaques and also form some deposits in the cerebrovasculature leading to cerebral amyloid angiopathy and hemorrhagic stroke. Functional vascular abnormalities are one of the earlier clinical manifestations in both sporadic and familial forms of AD. Most of the cardiovascular risk factors (for instance, diabetes, hypertension, high cholesterol levels, atherosclerosis and smoking) constitute risk factors for AD as well, suggesting that functional vascular abnormalities may contribute to AD pathology. We studied the effect of A beta on endothelin-1 induced vasoconstriction in isolated human cerebral arteries collected following rapid autopsies. We report that freshly solubilized A beta enhances endothelin-1 induced vasoconstriction in isolated human middle cerebral and basilar arteries. The vasoactive effect of A beta in these large human cerebral arteries is inhibited by NS-398, a selective cyclooxygenase-2 inhibitor and by SB202190, a specific p38 Mitogen Activated Protein Kinase inhibitor suggesting the involvement of a pro-inflammatory pathway. Using a scanner laser Doppler imager, we observed that cerebral blood flow is decreased in the double transgenic APPsw Alzheimer mouse (PS1/APPsw) compared to PS1 littermates and can be improved by chronic treatment with either NS-398 or SB202190. Altogether, our data suggest a link between inflammation and the compromised cerebral hemodynamics in AD.